Takeda Pharmaceutical Company Limited (TAK) P/E Ratio History
Historical price-to-earnings valuation from 2009 to 2025
Loading P/E history...
TAK Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Takeda Pharmaceutical Company Limited (TAK) trades at a price-to-earnings ratio of 77.4x, with a stock price of $16.64 and trailing twelve-month earnings per share of $35.80.
The current P/E is 26999% above its 5-year average of 0.3x. Over the past five years, TAK's P/E has ranged from a low of 0.1x to a high of 1.4x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TAK trades at a 247% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
The PEG ratio of 4.09 (P/E divided by -26% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, TAK commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TAK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TAK P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $203B | 12.6 | 0.61 | +2% | |
| $283B | 27.9 | 1.28 | +191% | |
| $104B | 18.1 | - | -7% | |
| $277B | 20.2 | 1.32 | +22% | |
| $102B | 6.7Lowest | 0.47Best | +348%Best | |
| $358B | 85.5 | - | -1% | |
| $115B | 16.3 | - | +178% | |
| $536B | 38.4 | - | -58% | |
| $277B | 15.4 | 0.73 | +8% | |
| $151B | 19.5 | - | -4% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TAK Historical P/E Data (2009–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | Wed Dec 31 2025 00:00:00 GM | $15.59 | $35.68 | 0.4x | -96% |
| FY2025 Q2 | $14.64 | $10.27 | 1.4x | -88% | |
| FY2025 Q1 | Mon Jun 30 2025 00:00:00 GM | $15.46 | $42.60 | 0.4x | -97% |
| FY2024 Q4 | Mon Mar 31 2025 00:00:00 GM | $14.87 | $33.45 | 0.4x | -96% |
| FY2024 Q3 | $13.24 | $65.11 | 0.2x | -98% | |
| FY2024 Q2 | Mon Sep 30 2024 00:00:00 GM | $14.22 | $90.95 | 0.2x | -99% |
| FY2024 Q1 | Sun Jun 30 2024 00:00:00 GM | $12.94 | $47.02 | 0.3x | -98% |
| FY2023 Q4 | Sun Mar 31 2024 00:00:00 GM | $13.89 | $45.61 | 0.3x | -97% |
| FY2023 Q3 | Sun Dec 31 2023 00:00:00 GM | $14.27 | $56.22 | 0.3x | -98% |
| FY2023 Q2 | Sat Sep 30 2023 00:00:00 GM | $15.47 | $60.80 | 0.3x | -98% |
| FY2023 Q1 | Fri Jun 30 2023 00:00:00 GM | $15.71 | $95.88 | 0.2x | -99% |
| FY2022 Q4 | Fri Mar 31 2023 00:00:00 GM | $16.48 | $101.10 | 0.2x | -99% |
Average P/E for displayed period: 11.5x
Full TAK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See TAK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TAK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TAK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTAK — Frequently Asked Questions
Quick answers to the most common questions about buying TAK stock.
Is TAK stock overvalued or undervalued?
TAK trades at 77.4x P/E, above its 5-year average of 0.3x. The 100th percentile ranking indicates a premium to historical valuation.
How does TAK's valuation compare to peers?
Takeda Pharmaceutical Company Limited P/E of 77.4x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is TAK's PEG ratio?
TAK PEG ratio is 4.09. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2009-2025.